Portfolio Scan: Rapid Exit Opportunity Assessment

We conduct a concise review of your current medtech holdings to identify which are best positioned for an early strategic exit within the next 6–18 months.

You’ll receive actionable intelligence — potential acquirer categories, readiness gaps, and realistic next steps — enabling informed capital allocation decisions.

Exit Roadmap for Capital-Constrained Specific Portfolio Company

When a portfolio company’s path to revenue is long, uncertain, or capital-intensive, an early exit can often produce a better outcome for all stakeholders.

Our Early Exit Roadmap process identifies qualified acquirers, defines achievable valuation scenarios, and aligns founders with investor objectives to move efficiently toward transaction readiness — without the overhead or posturing of traditional bankers.

Comprehensive Transaction Lead — Strategy to Close

When an exit opportunity emerges, we act as a discreet deal lead — coordinating diligence, aligning buyer–seller interests, and driving toward close.

Our focus is on achieving mutually beneficial outcomes that preserve relationships and enhance reputation with acquirers and LPs alike.